Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in Mice

Achondroplasia: Manifestations and Treatment

(2016) Eric D. Shirley et al.   JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS

Evaluation of the Therapeutic Potential of a CNP Analog in a Fgfr3 Mouse Model Recapitulating Achondroplasia

(2012) Florence Lorget et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Identification of Adipose Tissue Dendritic Cells Correlated With Obesity-Associated Insulin-Resistance and Inducing Th17 Responses in Mice and Patients

(2012) A. Bertola et al.   DIABETES

Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia

(2012) Y. Xie et al.   HUMAN MOLECULAR GENETICS

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia

(2012) Min Jin et al.   HUMAN MOLECULAR GENETICS

Direct Assessment of the Effect of the Gly380Arg Achondroplasia Mutation on FGFR3 Dimerization Using Quantitative Imaging FRET

(2012) Jesse Placone et al.   PLoS One

Clinical management of achondroplasia

(2011) M J Wright et al.   ARCHIVES OF DISEASE IN CHILDHOOD

FGFR3 Heterodimerization in Achondroplasia, the Most Common Form of Human Dwarfism

(2011) Lijuan He et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systemic Administration of C-Type Natriuretic Peptide as a Novel Therapeutic Strategy for Skeletal Dysplasias

(2009) Akihiro Yasoda et al.   ENDOCRINOLOGY

Persistent Expression of FLAG-tagged Micro dystrophin in Nonhuman Primates Following Intramuscular and Vascular Delivery

(2009) Louise R Rodino-Klapac et al.   MOLECULAR THERAPY